Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population
Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Participants will undertake a 12-week, open-label study of milnacipran in a
well-characterized cohort of patients with fibromyalgia syndrome (FMS) who are 65 years and
older to investigate the short-term efficacy and safety of this drug in the elderly
population. The investigators hypothesize that milnacipran will be effective in treating
fibromyalgia syndrome (FMS), and will be prove to be safe when patients are selected for the
absence of pre-existing blood pressure abnormalities and other serious medical conditions.